[go: up one dir, main page]

BRPI0511466A - agonistas peptìdicos do receptor de vasopressina - Google Patents

agonistas peptìdicos do receptor de vasopressina

Info

Publication number
BRPI0511466A
BRPI0511466A BRPI0511466-7A BRPI0511466A BRPI0511466A BR PI0511466 A BRPI0511466 A BR PI0511466A BR PI0511466 A BRPI0511466 A BR PI0511466A BR PI0511466 A BRPI0511466 A BR PI0511466A
Authority
BR
Brazil
Prior art keywords
compounds
vasopressin receptor
receptor peptide
peptide agonists
treatment
Prior art date
Application number
BRPI0511466-7A
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Claudio Schteingart
Regent Laporte
Robert Felix Galyean
Pierre J-M Riviere
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BRPI0511466A publication Critical patent/BRPI0511466A/pt
Publication of BRPI0511466B1 publication Critical patent/BRPI0511466B1/pt
Publication of BRPI0511466B8 publication Critical patent/BRPI0511466B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AGONISTAS PEPTìDICOS DO RECEPTOR DE VASOPRESSINA. A presente invenção refere-se a novos compostos, a composições farmacêuticas que os compreendem, ao uso dos ditos compostos para a fabricação de um medicamento para o tratamento de, entre outros, estados de choque, assim como a um método para o tratamento dos ditos estados, em que os ditos compostos são administrados. Os compostos são representados pela fórmula geral (I), conforme adicionalmente definida no relatório.
BRPI0511466A 2004-08-11 2005-08-03 agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes BRPI0511466B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60037704P 2004-08-11 2004-08-11
EP04019029.0 2004-08-11
EP04019029 2004-08-11
US60/600,377 2004-08-11
PCT/US2005/027772 WO2006020491A1 (en) 2004-08-11 2005-08-03 Peptidic vasopressin receptor agonists

Publications (3)

Publication Number Publication Date
BRPI0511466A true BRPI0511466A (pt) 2007-12-26
BRPI0511466B1 BRPI0511466B1 (pt) 2018-01-23
BRPI0511466B8 BRPI0511466B8 (pt) 2021-05-25

Family

ID=34926126

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511466A BRPI0511466B8 (pt) 2004-08-11 2005-08-03 agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes

Country Status (25)

Country Link
US (2) US8148319B2 (pt)
EP (1) EP1776133B1 (pt)
JP (1) JP4664363B2 (pt)
KR (1) KR100884323B1 (pt)
CN (1) CN1964732B (pt)
AR (1) AR050914A1 (pt)
AT (1) ATE509944T1 (pt)
AU (1) AU2005274070B2 (pt)
BR (1) BRPI0511466B8 (pt)
CA (1) CA2567797C (pt)
DK (1) DK1776133T3 (pt)
ES (1) ES2366702T3 (pt)
IL (1) IL178690A (pt)
JO (1) JO2937B1 (pt)
MX (1) MX2007001396A (pt)
NO (1) NO342449B1 (pt)
NZ (1) NZ550707A (pt)
PL (1) PL1776133T3 (pt)
PT (1) PT1776133E (pt)
RU (1) RU2355701C2 (pt)
SA (1) SA05260254B1 (pt)
SI (1) SI1776133T1 (pt)
TW (1) TWI364291B (pt)
WO (1) WO2006020491A1 (pt)
ZA (1) ZA200700772B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
AU2007215406B2 (en) * 2006-02-10 2011-12-08 Ferring B.V Novel compounds
HUE027174T2 (en) 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
EP2175874A2 (en) * 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
WO2010032140A2 (en) 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
US9388214B2 (en) 2014-11-05 2016-07-12 Ferring B.V. V1A receptor agonists
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
MA46586A (fr) 2016-10-21 2019-08-28 Chiasma Inc Compositions de terlipressine et leurs procédés d'utilisation
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
CN109748950B (zh) * 2017-11-02 2020-10-30 深圳翰宇药业股份有限公司 一种固相合成血管升压素受体肽激动剂selepressin的方法
EP3517543B1 (en) * 2018-01-30 2020-11-04 Bachem AG Manufacture of glucagon peptides
CN113164550A (zh) 2018-11-15 2021-07-23 费灵有限公司 用于治疗败血症的化合物、组合物和方法
JP2025532942A (ja) * 2022-09-30 2025-10-03 フェリング ベスローテン フェンノートシャップ 平均動脈圧を調節するための混合バソプレシン受容体アゴニスト－アンタゴニスト

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE651400A (pt) 1963-04-05 1965-02-04
NL129421C (pt) * 1963-08-30 1900-01-01
CS235151B1 (cs) 1982-08-26 1985-05-15 Michal Lebl Způsob dělení Dal isomerů analogů oxytocinu
US4829051A (en) 1983-04-05 1989-05-09 Vega Laboratories, Inc. N-substituted derivatives of 1-desaminovasopressin
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
CS242062B1 (cs) 1984-08-23 1986-04-17 Milan Zaoral Vasopresinová a vasotocinová analoga a způsob jejich přípravy
SE457055B (sv) 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
SE469473B (sv) 1987-10-07 1993-07-12 Ferring Ab Vasoaktiva peptider
SE502644C2 (sv) * 1990-02-27 1995-11-27 Ferring Ab Vasoaktiva vasotocinderivat
RU2063979C1 (ru) 1992-02-24 1996-07-20 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Пептиды последовательности окситоцина
US5516795A (en) * 1994-09-12 1996-05-14 Abbott Laboratories Heteroatom substituted propanyl derivatives having 5-lipoxygenase inhibitory activity
RU2073010C1 (ru) * 1994-10-26 1997-02-10 Российско-германское совместное предприятие "Константа" Способ синтеза лизин-вазопрессина в растворе
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
WO1999013092A1 (en) 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE0001440D0 (sv) 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
WO2002064740A2 (en) 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
AU2003220919A1 (en) * 2002-03-29 2003-10-13 Wakamoto Pharmaceutical Co., Ltd. Drugs for increasing lacrimal fluid
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
DE60333857D1 (de) 2002-10-03 2010-09-30 Neuropharmacology Services Llc Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
US7183255B2 (en) 2003-02-26 2007-02-27 Intradialytic Pharmaceuticals Method for stabilizing blood pressure in hemodialysis subjects
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
AU2007215406B2 (en) * 2006-02-10 2011-12-08 Ferring B.V Novel compounds
HUE027174T2 (en) * 2006-02-13 2016-10-28 Ferring Bv Use of peptide agonists of the vasopressin receptor
EP2120565B1 (en) 2006-12-20 2012-11-28 Merck Sharp & Dohme Corp. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
RU2342949C1 (ru) 2007-03-26 2009-01-10 Юрий Георгиевич Жуковский Применение [дезамино-1, изолейцин-3, аргинин-8]вазопрессина в качестве средства для увеличения выведения почкой солей натрия и усиления обратного избирательного всасывания из почечных канальцев в кровь воды-растворителя

Also Published As

Publication number Publication date
CN1964732A (zh) 2007-05-16
SA05260254B1 (ar) 2008-05-19
DK1776133T3 (da) 2011-07-18
AU2005274070B2 (en) 2008-02-07
ATE509944T1 (de) 2011-06-15
NO20071314L (no) 2007-05-10
KR100884323B1 (ko) 2009-02-18
RU2007101238A (ru) 2008-09-20
CA2567797A1 (en) 2006-02-23
JP2008509221A (ja) 2008-03-27
AU2005274070A1 (en) 2006-02-23
PL1776133T3 (pl) 2011-09-30
HK1100280A1 (en) 2007-09-14
IL178690A0 (en) 2007-02-11
EP1776133A4 (en) 2008-12-31
ZA200700772B (en) 2008-09-25
US20120196808A1 (en) 2012-08-02
ES2366702T3 (es) 2011-10-24
TWI364291B (en) 2012-05-21
IL178690A (en) 2013-10-31
EP1776133A1 (en) 2007-04-25
PT1776133E (pt) 2011-09-02
WO2006020491A1 (en) 2006-02-23
BRPI0511466B8 (pt) 2021-05-25
CN1964732B (zh) 2011-03-02
BRPI0511466B1 (pt) 2018-01-23
US20090054309A1 (en) 2009-02-26
US8148319B2 (en) 2012-04-03
NZ550707A (en) 2010-07-30
JP4664363B2 (ja) 2011-04-06
TW200612976A (en) 2006-05-01
SI1776133T1 (sl) 2011-07-29
EP1776133B1 (en) 2011-05-18
AR050914A1 (es) 2006-12-06
NO342449B1 (no) 2018-05-22
MX2007001396A (es) 2007-04-19
JO2937B1 (en) 2016-03-15
KR20070029183A (ko) 2007-03-13
RU2355701C2 (ru) 2009-05-20
US8778881B2 (en) 2014-07-15
CA2567797C (en) 2012-07-10

Similar Documents

Publication Publication Date Title
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
CY1109842T1 (el) Αναστολεις της αφυδρογονασης 11-β-υδροξυστεροειδων i
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
BRPI0511466A (pt) agonistas peptìdicos do receptor de vasopressina
CY1112398T1 (el) Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
EA201170772A1 (ru) Органические соединения
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
SE0401762D0 (sv) Novel compounds
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
BRPI0909737A2 (pt) compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos
JO2770B1 (en) Organic compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.